• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia.

作者信息

DiNardo Courtney D, Pratz Keith W, Panayiotidis Panayiotis, Wei Xudong, Vorobyev Vladimir, Illés Árpád, Kim Inho, Ivanov Vladimir, Ku Grace, Miller Catherine L, Zhang Meng, Tatsch Fernando, Potluri Jalaja, Schmidt Xenia, Récher Christian

机构信息

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

出版信息

Am J Hematol. 2025 Jan;100(1):185-188. doi: 10.1002/ajh.27515. Epub 2024 Nov 1.

DOI:10.1002/ajh.27515
PMID:39487568
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11625987/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/184a/11625987/1a7ffcf8347e/AJH-100-185-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/184a/11625987/1a7ffcf8347e/AJH-100-185-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/184a/11625987/1a7ffcf8347e/AJH-100-185-g001.jpg

相似文献

1
The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia.缓解后使用粒细胞集落刺激因子在维奈克拉联合治疗新诊断急性髓系白血病患者的3期研究中的影响
Am J Hematol. 2025 Jan;100(1):185-188. doi: 10.1002/ajh.27515. Epub 2024 Nov 1.
2
Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony-stimulating factor chemotherapy as a first-line therapy for newly diagnosed acute myeloid leukemia: A propensity score-matched analysis.维奈托克联合低甲基化药物与阿糖胞苷、阿克拉霉素和粒细胞集落刺激因子化疗作为初治急性髓系白血病的一线治疗：一项倾向评分匹配分析。
Cancer. 2024 Jul 15;130(14):2472-2481. doi: 10.1002/cncr.35278. Epub 2024 Mar 12.
3
A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.高危骨髓增生异常综合征和急性髓系白血病患者用维奈克拉治疗的真实土耳其经验。
Clin Lymphoma Myeloma Leuk. 2021 Aug;21(8):e686-e692. doi: 10.1016/j.clml.2021.04.004. Epub 2021 Apr 20.
4
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.维奈托克联合 FLAG-IDA 诱导和巩固治疗新诊断和复发/难治性急性髓系白血病。
J Clin Oncol. 2021 Sep 1;39(25):2768-2778. doi: 10.1200/JCO.20.03736. Epub 2021 May 27.
5
Venetoclax plus D-CAG (decitabine, cytarabine, aclarubicin, G-CSF) for elderly or unfit patients with newly diagnosed acute myeloid leukemia: a multicenter, prospective study.维奈托克联合D-CAG（地西他滨、阿糖胞苷、阿柔比星、粒细胞集落刺激因子）用于老年或身体状况不佳的新诊断急性髓系白血病患者：一项多中心前瞻性研究。
Ann Hematol. 2024 Dec;103(12):5315-5323. doi: 10.1007/s00277-024-06097-w. Epub 2024 Nov 26.
6
Impact on acute myeloid leukemia relapse in granulocyte colony-stimulating factor application: a meta-analysis.粒细胞集落刺激因子应用对急性髓系白血病复发的影响：一项荟萃分析。
Hematology. 2018 Oct;23(9):581-589. doi: 10.1080/10245332.2018.1446811. Epub 2018 Mar 8.
7
Real-World Experience with Venetoclax Treatment for Newly-Diagnosed Acute Myeloid Leukemia in Japan (VENUS Study): An Interim Analysis Focusing on Neutropenia Management.日本维奈托克治疗新诊断急性髓系白血病的真实世界经验（VENUS研究）：以中性粒细胞减少症管理为重点的中期分析
Oncol Ther. 2025 Mar 7. doi: 10.1007/s40487-025-00329-3.
8
Cladribine with Granulocyte Colony-Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study.克拉屈滨联合粒细胞集落刺激因子、阿糖胞苷和阿克拉霉素治疗难治/复发急性髓系白血病的 II 期多中心研究。
Oncologist. 2020 Nov;25(11):e1663-e1670. doi: 10.1634/theoncologist.2020-0818. Epub 2020 Sep 21.
9
Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy.维奈克拉用于治疗不符合强化化疗条件的新诊断急性髓系白血病患者。
Ther Adv Hematol. 2019 Oct 23;10:2040620719882822. doi: 10.1177/2040620719882822. eCollection 2019.
10
Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the treatment of myeloid leukemia.
Curr Opin Hematol. 1995 May;2(3):196-203. doi: 10.1097/00062752-199502030-00007.

引用本文的文献

1
Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms.不适合接受治疗的新诊断急性髓系白血病患者：2026年治疗算法
Blood Cancer J. 2025 Aug 16;15(1):139. doi: 10.1038/s41408-025-01346-1.
2
Length of Washout Period After Remission Does Not Influence Relapse Risk in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents Combined with Venetoclax.缓解后洗脱期的长短对接受去甲基化药物联合维奈克拉治疗的急性髓系白血病患者的复发风险无影响。
J Clin Med. 2025 Jul 15;14(14):5007. doi: 10.3390/jcm14145007.
3
Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days.

本文引用的文献

1
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.VIALE-A 研究的长期随访：不适合化疗的初治急性髓系白血病患者中应用维奈克拉联合阿扎胞苷。
Am J Hematol. 2024 Apr;99(4):615-624. doi: 10.1002/ajh.27246. Epub 2024 Feb 11.
2
Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy.VIALE-C研究对不符合强化化疗条件的初治急性髓系白血病患者的长期随访
Blood. 2022 Dec 22;140(25):2754-2756. doi: 10.1182/blood.2022016963.
3
Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A.
急性髓系白血病中维奈托克的给药方案：7天对比14天对比21天对比28天。
Blood Cancer J. 2025 Apr 3;15(1):56. doi: 10.1038/s41408-025-01270-4.
4
Real-World Experience with Venetoclax Treatment for Newly-Diagnosed Acute Myeloid Leukemia in Japan (VENUS Study): An Interim Analysis Focusing on Neutropenia Management.日本维奈托克治疗新诊断急性髓系白血病的真实世界经验（VENUS研究）：以中性粒细胞减少症管理为重点的中期分析
Oncol Ther. 2025 Mar 7. doi: 10.1007/s40487-025-00329-3.
VIALE-A研究中接受维奈克拉和阿扎胞苷治疗的急性髓系白血病患者缓解后血细胞减少的管理
Am J Hematol. 2022 Nov;97(11):E416-E419. doi: 10.1002/ajh.26692. Epub 2022 Sep 16.
4
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.成人 AML 的诊断与治疗：ELN 专家组代表发布的 2022 年国际专家建议
Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867.
5
Current state and future opportunities in granulocyte colony-stimulating factor (G-CSF).粒细胞集落刺激因子（G-CSF）的现状与未来机遇
Support Care Cancer. 2022 Sep;30(9):7067-7077. doi: 10.1007/s00520-022-07103-5.
6
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.阿扎胞苷和维奈托克治疗未经治急性髓系白血病。
N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971.